Role of Interleukin-22 and Innate Lymphoid Cells in Pancreas Cancer Initiation and Progression
Interleukin-22 和先天淋巴细胞在胰腺癌发生和进展中的作用
基本信息
- 批准号:9313852
- 负责人:
- 金额:$ 10.61万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-07-15 至 2021-06-30
- 项目状态:已结题
- 来源:
- 关键词:Active LearningAdhesivesAntibodiesBasic ScienceBenignBiological AssayBiological Response ModifiersBlood VesselsCancer BiologyCancer EtiologyCarcinomaCellsCessation of lifeChronicColon CarcinomaCytokine ActivationCytokine SignalingDNA Sequence AlterationDataDevelopmentDevelopment PlansDiagnosisDiseaseDoctor of PhilosophyDuctal Epithelial CellElementsEngraftmentEpithelial CellsEventExcisionGastrointestinal tract structureGenetic TranscriptionGenetically Engineered MouseGoalsGrowthHost DefenseHumanImmuneImmunologistImmunologyImmunotherapeutic agentIn VitroInflammationInvadedKnowledgeLeadLesionLinkLymphaticLymphoid CellMalignant - descriptorMalignant NeoplasmsMalignant neoplasm of pancreasMediatingMentorsMentorshipMethodsModelingMusNF-kappa BNeoplasm MetastasisOperative Surgical ProceduresOrganPancreasPancreatectomyPancreatic AdenocarcinomaPancreatic ductPancreatitisPathway interactionsPatientsPharmacologyPhenotypePlayPopulationPositioning AttributePremalignantProteinsPublishingRadiationRecombinant InterleukinsRegulationResearchResearch PersonnelResistanceRiskRoleSTAT3 geneSignal TransductionSiteSourceSpecimenStaining methodStainsT-LymphocyteTimeTissuesTrainingTransgenic OrganismsTumorigenicityUnited StatesWorkacute pancreatitisbasecancer initiationcancer invasivenesscareer developmentchemotherapychronic pancreatitiscytokineepithelial to mesenchymal transitionexperiencein vivointerestinterleukin-22malignant breast neoplasmmelanomamembermortalitymouse modelnew therapeutic targetpancreatic cancer cellspancreatic neoplasmreceptorrepairedtissue repairtranscription factortumortumor immunologytumor initiationtumor progressiontumorigenic
项目摘要
Project Summary/Abstract
Pancreas adenocarcinoma remains among the most lethal cancers with an expected 5-year survival of <5%.
There are over to 45,000 new diagnoses each year and a similar number of deaths making it the fourth most
common cause of cancer related mortality in the United States. Despite significant progress in breast cancer,
colon cancer and melanoma, there has been no appreciable change in the mortality from pancreas cancer in
the past four decades. Two factors that make pancreas cancer particularly difficult to treat are its relative
proclivity towards early dissemination and its resistance to chemotherapy and radiation. One proposed
mechanism that underlies both of these phenomena is epithelial to mesenchymal transition (EMT) in which
pancreatic ductal cells gain the ability to shed their polarity and adhesive proteins and invade through
surrounding stroma into blood vessels and lymphatics. We have identified elevated levels of the cytokine
interleukin-22 (IL-22) in pre-invasive and invasive pancreas cancers and demonstrated its ability to increase
transcription of genes that mediate EMT. We have also shown that IL-22 promotes invasion and proliferation of
pancreatic tumor cells, in-vitro, and tumor engraftment and growth, in-vivo. In this proposal, we will determine
how IL-22 leads to EMT in pancreas cancer cells and better determine its significance in cancer initiation and
progression, in-vivo. We will also explore the role of innate lymphoid cells as the intra-tumoral source of IL-22
both in mice and humans.
The overall goal of this application is to support my continued training and development to become an
independent investigator in tumor immunology and pancreas cancer biology. The career development plan is
based on formal didactic coursework, experiential learning and mentored basic science training. I have
received generous support and protected time from my department and will work closely with my mentor Dr.
Weiping Zou, MD, PhD, a respected and experienced tumor immunologist. I have also constructed a
mentorship committee, each of whom has expertise in immunology and/or pancreas cancer biology and is
tasked with furthering my development as a researcher and helping complete this project. My main research
goals are to determine the mechanisms by which IL-22 leads to EMT and determine its biologic significance in
an autochthonous pancreas cancer murine model. The major themes of the my research interests are reflected
in the Specific Aims of this proposal: (1) To determine how IL-22 signaling in pancreas cells leads to EMT, (2)
to determine the effect of IL-22 signaling on pancreas cancer initiation, progression and metastasis in a
genetically engineered mouse model of pancreas adenocarcinoma, and (3) to identify the predominant source
of IL-22 in pancreas tumors in both humans and mice.
Successful completion of these studies should increase our understanding of the role of innate inflammation in
pancreas cancer initiation and progression and provide new immunotherapeutic targets for this difficult to treat
malignancy.
项目摘要/摘要
胰腺腺癌仍然是最致命的癌症之一,预计5年生存率<5%。
每年有超过45,000个新诊断,死亡人数类似,使其成为第四大诊断
美国与癌症相关死亡率的常见原因。尽管在乳腺癌方面取得了重大进展,但
结肠癌和黑色素瘤,胰腺癌死亡率没有明显变化
过去的四十年。使胰腺癌特别难以治疗的两个因素是其相对
对早期传播及其对化学疗法和放射线的抵抗力的倾向。一个提议
这两种现象的基础的机制都是间质转变(EMT)的上皮
胰腺导管细胞具有脱离其极性和粘合蛋白的能力,并通过
围绕基质进入血管和淋巴管。我们已经确定了细胞因子的升高水平
介入前和侵入性胰腺癌中的白介素22(IL-22),并证明了其增加的能力
介导EMT的基因的转录。我们还表明,IL-22促进了入侵和增殖
胰腺肿瘤细胞,体外,肿瘤植入和生长,体内。在此提案中,我们将确定
IL-22如何导致胰腺癌细胞EMT,并更好地确定其在癌症开始和
进展,体内。我们还将探索先天淋巴样细胞作为IL-22的肿瘤内来源的作用
在老鼠和人类中。
该应用程序的总体目标是支持我的持续培训和发展,以成为
肿瘤免疫学和胰腺癌生物学的独立研究者。职业发展计划是
基于正式的教学课程,体验式学习和指导基础科学培训。我有
得到了我部门的慷慨支持和保护时间,并将与我的导师博士紧密合作。
Weiping Zou,MD,PhD,一位受人尊敬且经验丰富的肿瘤免疫学家。我也构建了
指导委员会,每个委员会在免疫学和/或胰腺癌生物学方面都有专业知识,并且是
负责进一步发展我作为研究人员的发展并帮助完成该项目。我的主要研究
目标是确定IL-22导致EMT并确定其生物学意义的机制
一种自我卫生胰腺癌鼠模型。我的研究兴趣的主要主题反映了
在该提案的具体目的中:(1)确定胰腺细胞中的IL-22信号如何导致EMT,(2)
确定IL-22信号转导对胰腺癌的启动,进展和转移的影响
胰腺腺癌的基因工程小鼠模型和(3)以识别主要来源
人类和小鼠的胰腺肿瘤中的IL-22。
这些研究的成功完成应增加我们对先天炎症在
胰腺癌的启动和进展,并为这种难以治疗的新免疫治疗靶标提供
恶性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Timothy Louis Frankel其他文献
Timothy Louis Frankel的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Timothy Louis Frankel', 18)}}的其他基金
Mechanisms of myeloid cell driven pancreatic plasticity and carcinogenesis
骨髓细胞驱动胰腺可塑性和致癌机制
- 批准号:
10607213 - 财政年份:2023
- 资助金额:
$ 10.61万 - 项目类别:
Role of environmental toxins in shaping the tumor immune microenvironment
环境毒素在塑造肿瘤免疫微环境中的作用
- 批准号:
10366833 - 财政年份:2022
- 资助金额:
$ 10.61万 - 项目类别:
Role of environmental toxins in shaping the tumor immune microenvironment
环境毒素在塑造肿瘤免疫微环境中的作用
- 批准号:
10644980 - 财政年份:2022
- 资助金额:
$ 10.61万 - 项目类别:
Epithelial-immune cell crosstalk during injury and recovery in acute pancreatitis
急性胰腺炎损伤和恢复过程中上皮-免疫细胞的串扰
- 批准号:
10363904 - 财政年份:2021
- 资助金额:
$ 10.61万 - 项目类别:
Epithelial-immune cell crosstalk during injury and recovery in acute pancreatitis
急性胰腺炎损伤和恢复过程中上皮-免疫细胞的串扰
- 批准号:
10543109 - 财政年份:2021
- 资助金额:
$ 10.61万 - 项目类别:
相似国自然基金
基于短肽诱导蚕丝蛋白组装的可控粘附生物粘合剂的制备及粘附性能研究
- 批准号:52303272
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
氮杂环丙烷基聚多硫化物可逆粘合剂的分子设计与制备
- 批准号:22378080
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
多酚功能化壳聚糖基组织粘合剂构建及其能量耗散机制探究
- 批准号:82302389
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
负载MUR仿生脂质体粘合剂靶向调控荷菌巨噬细胞IFI204/ARMCX3/Caspase-11焦亡抑制创伤性骨髓炎发生的机制研究
- 批准号:82372421
- 批准年份:2023
- 资助金额:48 万元
- 项目类别:面上项目
多尺度低表面能粘合剂的构筑及织物基传感器稳定性提升机制研究
- 批准号:22302110
- 批准年份:2023
- 资助金额:30.00 万元
- 项目类别:青年科学基金项目
相似海外基金
Bio-Responsive and Immune Protein-Based Therapies for Inhibition of Proteolytic Enzymes in Dental Tissues
用于抑制牙齿组织中蛋白水解酶的基于生物响应和免疫蛋白的疗法
- 批准号:
10555093 - 财政年份:2023
- 资助金额:
$ 10.61万 - 项目类别:
Localized mitochondrial metabolic activity in Xenopus mesendoderm cells undergoing collective cell migration
爪蟾中内胚层细胞集体细胞迁移的局部线粒体代谢活性
- 批准号:
10751722 - 财政年份:2023
- 资助金额:
$ 10.61万 - 项目类别:
FimH-Targeting Antibody-Recruiting Molecules as Novel Drugs for Preventing Complicated Urinary Tract Infections
FimH 靶向抗体招募分子作为预防复杂性尿路感染的新药
- 批准号:
10603693 - 财政年份:2023
- 资助金额:
$ 10.61万 - 项目类别:
Optimization of protective antibodies response against bacterial adhesins
针对细菌粘附素的保护性抗体反应的优化
- 批准号:
10731509 - 财政年份:2023
- 资助金额:
$ 10.61万 - 项目类别:
Identifying Mechanisms Involved in Hydroxyurea-Mediated Reduction in Vaso-occlusive Adhesive Events in Sickle Cell Disease
确定羟基脲介导的镰状细胞病血管闭塞性粘附事件减少机制
- 批准号:
10724590 - 财政年份:2023
- 资助金额:
$ 10.61万 - 项目类别: